Published in Biochim Biophys Acta on October 12, 1994
Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine (2006) 4.08
Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J (2007) 2.38
Protein adsorption on surfaces with grafted polymers: a theoretical approach. Biophys J (1997) 2.26
Multifunctional and stimuli-sensitive pharmaceutical nanocarriers. Eur J Pharm Biopharm (2008) 1.78
Ferri-liposomes as an MRI-visible drug-delivery system for targeting tumours and their microenvironment. Nat Nanotechnol (2011) 1.41
Lipid membrane expansion and micelle formation by polymer-grafted lipids: scaling with polymer length studied by spin-label electron spin resonance. Biophys J (2001) 1.40
Drug delivery trends in clinical trials and translational medicine: challenges and opportunities in the delivery of nucleic acid-based therapeutics. J Pharm Sci (2011) 1.24
Anthracycline antibiotics non-covalently incorporated into the block copolymer micelles: in vivo evaluation of anti-cancer activity. Br J Cancer (1996) 1.15
Delivery of nanomedicines to extracellular and intracellular compartments of a solid tumor. Adv Drug Deliv Rev (2011) 1.11
Experimental and Monte Carlo simulation studies of the thermodynamics of polyethyleneglycol chains grafted to lipid bilayers. Biophys J (1998) 1.08
Hydration of polyethylene glycol-grafted liposomes. Biophys J (1998) 1.05
Immunoconjugates and long circulating systems: origins, current state of the art and future directions. Adv Drug Deliv Rev (2012) 1.05
Nanoparticle characterization: state of the art, challenges, and emerging technologies. Mol Pharm (2013) 1.04
The effects of ethylene oxide containing lipopolymers and tri-block copolymers on lipid bilayers of dipalmitoylphosphatidylcholine. Biophys J (1997) 1.02
Exchange of monooleoylphosphatidylcholine as monomer and micelle with membranes containing poly(ethylene glycol)-lipid. Biophys J (1997) 0.98
Cytoplasmic delivery of liposomes into MCF-7 breast cancer cells mediated by cell-specific phage fusion coat protein. Mol Pharm (2010) 0.98
Impact of hapten presentation on antibody binding at lipid membrane interfaces. Biophys J (2008) 0.97
Curb challenges of the "Trojan Horse" approach: smart strategies in achieving effective yet safe cell-penetrating peptide-based drug delivery. Adv Drug Deliv Rev (2013) 0.97
Effect of cholesterol nanodomains on the targeting of lipid-based gene delivery in cultured cells. Mol Pharm (2010) 0.95
Immunogenicity of membrane-bound HIV-1 gp41 membrane-proximal external region (MPER) segments is dominated by residue accessibility and modulated by stereochemistry. J Biol Chem (2013) 0.93
Liposomal Cu-64 labeling method using bifunctional chelators: poly(ethylene glycol) spacer and chelator effects. Bioconjug Chem (2010) 0.93
Size and structure of spontaneously forming liposomes in lipid/PEG-lipid mixtures. Biophys J (2002) 0.90
The effect of cholesterol domains on PEGylated liposomal gene delivery in vitro. Ther Deliv (2011) 0.89
Protected Graft Copolymer (PGC) in Imaging and Therapy: A Platform for the Delivery of Covalently and Non-Covalently Bound Drugs. Theranostics (2012) 0.88
Positron emission tomography image-guided drug delivery: current status and future perspectives. Mol Pharm (2014) 0.88
The pharmacokinetics of Zr-89 labeled liposomes over extended periods in a murine tumor model. Nucl Med Biol (2014) 0.86
Development of the novel PEG-PE-based polymer for the reversible attachment of specific ligands to liposomes: synthesis and in vitro characterization. Bioconjug Chem (2011) 0.85
Surface functionalization of doxorubicin-loaded liposomes with octa-arginine for enhanced anticancer activity. Eur J Pharm Biopharm (2013) 0.85
In vivo theranostics at the peri-infarct region in cerebral ischemia. Theranostics (2013) 0.84
Positron emission tomography imaging of the stability of Cu-64 labeled dipalmitoyl and distearoyl lipids in liposomes. J Control Release (2011) 0.84
Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come. Pharmacol Rev (2016) 0.84
The use of convection-enhanced delivery with liposomal toxins in neurooncology. Toxins (Basel) (2011) 0.83
Ligands located within a cholesterol domain enhance gene delivery to the target tissue. J Control Release (2012) 0.83
Post-modification of preformed liposomes with novel non-phospholipid poly(ethylene glycol)-conjugated hexadecylcarbamoylmethyl hexadecanoic acid for enhanced circulation persistence in vivo. Int J Pharm (2013) 0.83
Dendrimers for siRNA Delivery. Pharmaceuticals (Basel) (2013) 0.82
Doxorubicin in TAT peptide-modified multifunctional immunoliposomes demonstrates increased activity against both drug-sensitive and drug-resistant ovarian cancer models. Cancer Biol Ther (2013) 0.80
Future applications of contrast ultrasound. J Cardiovasc Ultrasound (2011) 0.80
Interactions of adriamycin, cytochrome c, and serum albumin with lipid monolayers containing poly(ethylene glycol)-ceramide. Biophys J (2002) 0.80
Low molecular weight chitosan-coated polymeric nanoparticles for sustained and pH-sensitive delivery of paclitaxel. J Drug Target (2015) 0.79
Immunoliposome-PCR: a generic ultrasensitive quantitative antigen detection system. J Nanobiotechnology (2012) 0.79
Accelerated blood clearance phenomenon upon cross-administration of PEGylated nanocarriers in beagle dogs. Int J Nanomedicine (2015) 0.78
Terminal PEGylated DNA-Gold Nanoparticle Conjugates Offering High Resistance to Nuclease Degradation and Efficient Intracellular Delivery of DNA Binding Agents. ACS Appl Mater Interfaces (2015) 0.78
Local and average gloss from flat-faced sodium chloride tablets. AAPS PharmSciTech (2006) 0.78
Non-viral therapeutic approaches to ocular diseases: An overview and future directions. J Control Release (2015) 0.78
Preparation and nanoencapsulation of l-asparaginase II in chitosan-tripolyphosphate nanoparticles and in vitro release study. Nanoscale Res Lett (2014) 0.77
Micelle-like nanoparticles as carriers for DNA and siRNA. Mol Pharm (2015) 0.77
Sustained liver targeting and improved antiproliferative effect of doxorubicin liposomes modified with galactosylated lipid and PEG-lipid. AAPS PharmSciTech (2010) 0.77
Hepatic RNA Interference: Delivery by Synthetic Vectors. Drug Deliv Transl Res (2014) 0.77
Recent trends of polymer mediated liposomal gene delivery system. Biomed Res Int (2014) 0.76
Anti-cancer activity of doxorubicin-loaded liposomes co-modified with transferrin and folic acid. Eur J Pharm Biopharm (2016) 0.76
Temporal assessment of nanoparticle accumulation after experimental brain injury: Effect of particle size. Sci Rep (2016) 0.76
Inhibition of the Growth of Plasmodium falciparum in Culture by Stearylamine-Phosphatidylcholine Liposomes. J Parasitol Res (2011) 0.76
Investigation of enzyme-sensitive lipid nanoparticles for delivery of siRNA to blood-brain barrier and glioma cells. Int J Nanomedicine (2015) 0.75
Glutaric acid as a spacer facilitates improved intracellular uptake of LHRH-SPION into human breast cancer cells. Int J Nanomedicine (2007) 0.75
Targeting melanoma with immunoliposomes coupled to anti-MAGE A1 TCR-like single-chain antibody. Int J Nanomedicine (2016) 0.75
Targeting ischemic penumbra Part II: selective drug delivery using liposome technologies. J Exp Stroke Transl Med (2011) 0.75
Polymer-based gene delivery with low cytotoxicity by a unique balance of side-chain termini. Proc Natl Acad Sci U S A (2001) 1.76
Vascular permeability in a human tumour xenograft: molecular charge dependence. Br J Cancer (2000) 1.60
Localization of the 3' end of Escherichia coli 16 S RNA by electron microscopy of antibody-labelled subunits. J Mol Biol (1979) 1.59
Improving MR quantification of regional blood volume with intravascular T1 contrast agents: accuracy, precision, and water exchange. Magn Reson Med (1996) 1.48
The nucleotide sequence of the gene coding for the 16S rRNA from the archaebacterium Halobacterium halobium. Gene (1985) 1.40
Creation of a general model of RNA spatial organization. Trends Biochem Sci (1989) 1.38
A new macromolecule as a contrast agent for MR angiography: preparation, properties, and animal studies. Radiology (1993) 1.32
An enzymatic approach for localization of oligodeoxyribonucleotide binding sites on RNA. Application to studying rRNA topography. FEBS Lett (1981) 1.29
The 3'-terminal nucleotide sequence of the Halobacterium halobium 16 S rRNA. FEBS Lett (1982) 1.27
Unusual ribosome binding properties of mRNA encoding bacteriophage lambda repressor. Nucleic Acids Res (1992) 1.26
Three-dimensional structure of a human immunoglobulin with a hinge deletion. Proc Natl Acad Sci U S A (1993) 1.26
Mechanisms of ligand binding by monoclonal anti-fluorescyl antibodies. J Biol Chem (1982) 1.22
Topography of RNA in the ribosome: location of the 3'-end of 5 S RNA on the central protuberance of the 50 S subunit. FEBS Lett (1980) 1.21
The primary and secondary structure of the 5'-end region of encephalomyocarditis virus RNA. A novel approach to sequencing long RNA molecules. Gene (1983) 1.20
Topography of rna in the ribosome localization of the 16 s rna 5' end by immune electron microscopy. J Mol Biol (1982) 1.18
Modification of 18 S rRNA in the 40 S ribosomal subunit of yeast with dimethyl sulfate. FEBS Lett (1981) 1.17
Amphiphilic vinyl polymers effectively prolong liposome circulation time in vivo. Biochim Biophys Acta (1994) 1.17
Parameters for the interaction of ribosomal proteins L5, L18, and L25 with 5S RNA from Escherichia coli. Biochemistry (1978) 1.16
Thermodynamic properties of ligand binding by monoclonal anti-fluorescyl antibodies. Biochemistry (1986) 1.09
Multiple-analyte fluoroimmunoassay using an integrated optical waveguide sensor. Anal Chem (1999) 1.09
Measuring the mechanical stress induced by an expanding multicellular tumor system: a case study. Exp Cell Res (2003) 1.08
Topography of RNA in the ribosome: localization of the 3'-end of the 23 S rna on the surface of the 50 S ribosomal subunit by immune electron microscopy. FEBS Lett (1980) 1.04
Specific fragmentation of tRNA and rRNA at a 7-methylguanine residue in the presence of methylated carrier RNA. Eur J Biochem (1985) 1.03
Addressed fragmentation of RNA Molecules. FEBS Lett (1979) 1.03
How does the mRNA pass through the ribosome? Biochimie (1992) 1.03
Localization of 5' and 3' ends of the ribosome-bound segment of template polynucleotides by immune electron microscopy. EMBO J (1983) 1.02
The fusion of artificial lipid membranes induced by the synthetic arenavirus 'fusion peptide'. Biochim Biophys Acta (1992) 1.02
Three-dimensional structure of a light chain dimer crystallized in water. Conformational flexibility of a molecule in two crystal forms. J Mol Biol (1989) 1.01
Segments of the 16 S RNA located on the surface of the 30 S subunits of Escherichia coli ribosomes. FEBS Lett (1980) 1.01
The structure of the covalent linkage between proteins and RNA in encephalomyocarditis virus. Nucleic Acids Res (1980) 1.01
Proteins covalently linked to viral genomes. Prog Nucleic Acid Res Mol Biol (1987) 1.01
Circularity and cross-linking in preparations of replicative form of encephalomyocarditis virus RNA. J Mol Biol (1972) 1.00
The role of protein charge in protein-lipid interactions. pH-dependent changes of the electrophoretic mobility of liposomes through adsorption of water-soluble, globular proteins. Biochemistry (1993) 1.00
Investigation of specific binding of antifluorescyl antibody and Fab to fluorescein lipids in Langmuir-Blodgett deposited films using quartz crystal microbalance methodology. Anal Chem (1994) 1.00
A search for site-filling ligands in the Mcg Bence-Jones dimer: crystal binding studies of fluorescent compounds. Mol Immunol (1984) 0.99
[Construction and expression of genes encoding short hybrid mRNA in Escherichia coli]. Dokl Akad Nauk SSSR (1986) 0.98
Molecular dynamics of the anti-fluorescein 4-4-20 antigen-binding fragment. 1. Computer simulations. Biochemistry (1995) 0.96
Internal ribosome entry site of encephalomyocarditis virus RNA is unable to direct translation in Saccharomyces cerevisiae. FEBS Lett (1993) 0.96
Role of electrostatic interactions in the binding of fluorescein by anti-fluorescein antibody 4-4-20. Biochemistry (1993) 0.96
Micellar delivery of doxorubicin and its paramagnetic analog, ruboxyl, to HL-60 cells: effect of micelle structure and ultrasound on the intracellular drug uptake. J Control Release (1999) 0.96
Mutations at position A960 of E. coli 23 S ribosomal RNA influence the structure of 5 S ribosomal RNA and the peptidyltransferase region of 23 S ribosomal RNA. J Mol Biol (2000) 0.95
Molecular dynamics of the anti-fluorescein 4-4-20 antigen-binding fragment. 2. Time-resolved fluorescence spectroscopy. Biochemistry (1995) 0.94
MR lymphography with a lymphotropic T1-type MR contrast agent: Gd-DTPA-PGM. Magn Reson Med (1995) 0.94
Temperature-dependent aggregation of pH-sensitive phosphatidyl ethanolamine-oleic acid-cholesterol liposomes as measured by fluorescent spectroscopy. Anal Biochem (1992) 0.93
Toxicity and immunogenicity of Neisseria meningitidis lipopolysaccharide incorporated into liposomes. Infect Immun (1992) 0.91
Kinetics and mechanism of deuterium oxide-induced fluorescence enhancement of fluorescyl ligand bound to specific heterogeneous and homogeneous antibodies. J Biol Chem (1981) 0.91
Liposomal diamidine (imidocarb): preparation and animal studies. J Microencapsul (1995) 0.90
Structure of 5S rRNA within the Escherichia coli ribosome: iodine-induced cleavage patterns of phosphorothioate derivatives. RNA (1998) 0.90
First order dissociation rates between a subpopulation of high affinity rabbit anti-fluorescyl IgG antibody and homologous ligand. Mol Immunol (1980) 0.89
Complex of transfer-messenger RNA and elongation factor Tu. Unexpected modes of interaction. J Biol Chem (2001) 0.89
Differences in crystal properties and ligand affinities of an antifluorescyl Fab (4-4-20) in two solvent systems. Proteins (1988) 0.89
5S rRNA sugar-phosphate backbone protection in complexes with specific ribosomal proteins. FEBS Lett (1996) 0.89
Increasing antimicrobial resistance in gram-negative bacilli isolated from patients in intensive care units. Am J Infect Control (2000) 0.88
New synthetic amphiphilic polymers for steric protection of liposomes in vivo. J Pharm Sci (1995) 0.87
Macromolecular intravenous contrast agent for MR lymphography: characterization and efficacy studies. Radiology (1996) 0.87
[Initiation of RNA synthesis by the encephalomyocarditis virus in a cell-free system and the possible participation of VPg protein in this process]. Dokl Akad Nauk SSSR (1982) 0.87
Fluorescent probe studies of the interactions of 1-alkyl-2-pyrrolidones with stratum corneum lipid liposomes. J Pharm Sci (1996) 0.86
MR lymphography: study of a high-efficiency lymphotrophic agent. Radiology (1994) 0.85
Encephalomyocarditis virus RNA synthesis in vitro is protein-primed. EMBO J (1984) 0.85
[Study of ribosome structure using the biochemical methods: judgment day]. Mol Biol (Mosk) (2001) 0.85
A study of the interaction of TMV protein with single- and double-stranded polynucleotides. FEBS Lett (1976) 0.85
Prothymosin alpha fragmentation in apoptosis. FEBS Lett (2000) 0.84
Pressure-induced conformational changes in a human Bence-Jones protein (Mcg). Biochemistry (1985) 0.84
A new technique for the characterization of long-range tertiary contacts in large RNA molecules: insertion of a photolabel at a selected position in 16S rRNA within the Escherichia coli ribosome. Nucleic Acids Res (1997) 0.84
[Alkaline phosphatase linked with ribosomes in Escherichia coli]. Biokhimiia (1967) 0.84
Topography of RNA in the ribosome: location of the 5 S RNA residues A39 and U40 on the central protuberance of the 50 S subunit. FEBS Lett (1985) 0.84
Surface topography of ribosomal RNA. Methods Enzymol (1988) 0.84
Continuous assessment of perfusion by tagging including volume and water extraction (CAPTIVE): a steady-state contrast agent technique for measuring blood flow, relative blood volume fraction, and the water extraction fraction. Magn Reson Med (1998) 0.84
Analytical approaches to the study of monoclonal antibody stability. Pharm Res (1990) 0.84
An enzyme which specifically splits a covalent bond between picornaviral RNA and VPg. FEBS Lett (1988) 0.83
Photopatterning of antibodies on biosensors. Bioconjug Chem (2000) 0.83
Bayesian forecasting of serum vancomycin concentrations in neonates and infants. Ther Drug Monit (1995) 0.83
[Localization of mRNA segments, screened by ribosomes in initiator complexes with the help of a reverse transcription reaction]. Dokl Akad Nauk SSSR (1989) 0.83
Interaction of mRNA with the Escherichia coli ribosome: accessibility of phosphorothioate-containing mRNA bound to ribosomes for iodine cleavage. Nucleic Acids Res (1996) 0.83
Non-random conformation of a mouse IgG2a monoclonal antibody at low pH. Eur J Biochem (1991) 0.83
[A study of the formation of E. coli alkaline phosphatase macrostructure in the course of its biosynthesis]. Biokhimiia (1968) 0.83
Chemical ligation of DNA: the first non-enzymatic assembly of a biologically active gene. Nucleic Acids Res (1991) 0.83
Reassembly of TMV 20-S protein disks with 3-S RNA fragments. Virology (1975) 0.83
Telomerase from Saccharomyces cerevisiae contains several protein subunits and may have different activities depending on the protein content. FEBS Lett (1998) 0.83
Synthesis of a macromolecular camptothecin conjugate with dual phase drug release. Mol Pharm (2005) 0.82
On the interaction between a bactericidal antibody and a PorA epitope of Neisseria meningitidis in outer membrane vesicles: a competitive fluorescence polarization immunoassay. Anal Biochem (1997) 0.82
Use of synthetic peptides as tracer antigens in fluorescence polarization immunoassays of high molecular weight analytes. Anal Chem (1993) 0.82
Active site structure and antigen binding properties of idiotypically cross-reactive anti-fluorescein monoclonal antibodies. J Biol Chem (1990) 0.82
[Photoaffinity modification of small ribosomal subunits of Escherichia coli with 5'-diaziryl derivatives of mRNA]. Dokl Akad Nauk SSSR (1990) 0.82
Fluorescence anisotropy studies on the interaction of the short chain n-alkanols with stratum corneum lipid liposomes (SCLL) and distearoylphosphatidylcholine (DSPC)/distearoylphosphatidic acid (DSPA) liposomes. Biochim Biophys Acta (1993) 0.82
[Electrophoresis of ribosomes and ribosomal RNA in polyacrylamide gel]. Biokhimiia (1970) 0.81
Analysis of heterogeneous dissociation kinetics in polyclonal populations of rabbit anti-fluorescyl-IgG antibodies. Mol Immunol (1983) 0.81
The role of ribonucleic acids in the organization and functioning of ribosomes of E. coli. Subcell Biochem (1980) 0.80
RNA-RNA and RNA-protein interactions in 30 S ribosomal subunits. Association of 16 S rRNA fragments in the presence of ribosomal proteins. FEBS Lett (1991) 0.80
Effect of point mutations at position 89 of the E. coli 5S rRNA on the assembly and activity of the large ribosomal subunit. FEBS Lett (1998) 0.80
Thermodynamic analysis of the interaction between a bactericidal antibody and a PorA epitope of Neisseria meningitidis. Biochemistry (1997) 0.79